Stock Runners: TheStreet, Inc. (NASDAQ:TST), Amicus Therapeutics, Inc. (NASDAQ:FOLD), CEB Inc. (NYSE:CEB), Inc. (NASDAQ:STMP), Celldex Therapeutics, Inc. (NASDAQ:CLDX)

On 25 April, TheStreet, Inc. (NASDAQ:TST) announced the results of its quarterly rankings of the top firms and professionals involved in active bankruptcy cases for the first quarter of 2016. Collected data captures only active bankruptcy work for ongoing U.S. and Canadian cases.

TheStreet, Inc. (NASDAQ:TST) belongs to Technology sector. Its net profit margin is -2.90%. On last trading day company shares ended up at $1.13. TheStreet, Inc. (NASDAQ:TST) distance from 50-day simple moving average (SMA50) is 0.77%.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares decreased -0.39% in last trading session and ended the day at $7.75. FOLD return on assets is -21.20%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly performance is 34.08%.
TheStreet upgraded shares of CEB Inc (NYSE:CEB) from a hold rating to a buy rating in a research report sent to investors on Wednesday, reports.

On 28 April, CEB Inc. (NYSE:CEB) shares moved up 0.57% and was closed at $63.37. CEB EPS growth in last 5 year was 12.80%. CEB Inc. (NYSE:CEB) year to date (YTD) performance is 3.94%. Inc. (NASDAQ:STMP) announced an invitation to join the First Quarter 2016 Financial Results Conference Call. The call will take place Monday, May 9, 2016, at 5:00 pm ET and will be webcast from our Investor Relations website at The first quarter 2016 earnings press release will precede the earnings call at 4:30 pm ET on May 9, 2016. Inc. (NASDAQ:STMP) ended the last trading day at $82.46. Company weekly volatility is calculated as 5.61% and price to cash ratio as 19.37. Inc. (NASDAQ:STMP) showed a weekly performance of -13.79%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have progressed on prior platinum-based chemotherapy. 

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares advanced 2.70% in last trading session and ended the day at $4.19. CLDX return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -50.41%.

Leave a Reply

Your email address will not be published. Required fields are marked *